Patient characteristics
| Variable . | No IFN . | IFN . | P . |
|---|---|---|---|
| N (%) | 251 (34) | 489 (66) | |
| Registry, N | .26 | ||
| IBMTR | 94 | 204 | |
| NMDP | 157 | 285 | |
| Age, y (median, range) | 37 (16-58) | 37 (16-62) | .85 |
| Donor age, y (median, range)* | 36 (21-56) | 37 (19-58) | .81 |
| Male, N (%) | 155 (62) | 281 (57) | .26 |
| Donor-sex match (%)* | .38 | ||
| M into M | 110 (44) | 181 (37) | |
| M into F | 49 (20) | 106 (22) | |
| F into M | 44 (18) | 99 (20) | |
| F into F | 47 (19) | 98 (20) | |
| Caucasian, N (%) | 243 (97) | 441 (90) | .002 |
| CMV+ patient or donor, N (%)* | 141 (57) | 322 (67) | .01 |
| Conditioning regimen, N (%) | .82 | ||
| Cytoxan + TBI +/− other | 203 (81) | 386 (79) | |
| Busulfan + cytoxan +/− other | 45 (18) | 97 (20) | |
| Other | 3 (1) | 6 (1) | |
| Year of transplant, N | < .0001 | ||
| 1991 | 17 | 10 | |
| 1992 | 21 | 26 | |
| 1993 | 44 | 33 | |
| 1994 | 44 | 73 | |
| 1995 | 40 | 119 | |
| 1996 | 38 | 123 | |
| 1997 | 47 | 105 | |
| N survivors at last follow-up | 123 | 254 | † |
| Follow-up survivors, y (median, range) | 4.1 (0.7-8.3) | 3.1 (0.3-8.7) | < .0001 |
| Cause of death, N (%) | .20 | ||
| Primary disease | 8 (6) | 6 (3) | |
| Acute GVHD | 30 (23) | 38 (16) | |
| Chronic GVHD | 17 (13) | 33 (14) | |
| Infection | 29 (23) | 56 (24) | |
| Other | 34 (27) | 83 (35) | |
| Missing | 10 (8) | 19 (8) |
| Variable . | No IFN . | IFN . | P . |
|---|---|---|---|
| N (%) | 251 (34) | 489 (66) | |
| Registry, N | .26 | ||
| IBMTR | 94 | 204 | |
| NMDP | 157 | 285 | |
| Age, y (median, range) | 37 (16-58) | 37 (16-62) | .85 |
| Donor age, y (median, range)* | 36 (21-56) | 37 (19-58) | .81 |
| Male, N (%) | 155 (62) | 281 (57) | .26 |
| Donor-sex match (%)* | .38 | ||
| M into M | 110 (44) | 181 (37) | |
| M into F | 49 (20) | 106 (22) | |
| F into M | 44 (18) | 99 (20) | |
| F into F | 47 (19) | 98 (20) | |
| Caucasian, N (%) | 243 (97) | 441 (90) | .002 |
| CMV+ patient or donor, N (%)* | 141 (57) | 322 (67) | .01 |
| Conditioning regimen, N (%) | .82 | ||
| Cytoxan + TBI +/− other | 203 (81) | 386 (79) | |
| Busulfan + cytoxan +/− other | 45 (18) | 97 (20) | |
| Other | 3 (1) | 6 (1) | |
| Year of transplant, N | < .0001 | ||
| 1991 | 17 | 10 | |
| 1992 | 21 | 26 | |
| 1993 | 44 | 33 | |
| 1994 | 44 | 73 | |
| 1995 | 40 | 119 | |
| 1996 | 38 | 123 | |
| 1997 | 47 | 105 | |
| N survivors at last follow-up | 123 | 254 | † |
| Follow-up survivors, y (median, range) | 4.1 (0.7-8.3) | 3.1 (0.3-8.7) | < .0001 |
| Cause of death, N (%) | .20 | ||
| Primary disease | 8 (6) | 6 (3) | |
| Acute GVHD | 30 (23) | 38 (16) | |
| Chronic GVHD | 17 (13) | 33 (14) | |
| Infection | 29 (23) | 56 (24) | |
| Other | 34 (27) | 83 (35) | |
| Missing | 10 (8) | 19 (8) |